Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Injectable BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
Latest Information Update: 23 Jan 2025
At a glance
- Drugs BL-M02D1 (Primary)
- Indications Breast cancer; Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 20 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 20 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
- 17 Jun 2024 Planned End Date changed from 1 May 2024 to 1 Dec 2024.